Capricor Therapeutics, Inc. has recently released its 10-K report, detailing its operations and financial performance. The company, founded in 2005 and headquartered in San Diego, California, is a clinical-stage biotechnology firm focused on developing transformative cell and exosome-based therapeutics. Its lead product candidate, Deramiocel, is an allogeneic cardiosphere-derived cell in phase 3 clinical trial for the treatment of Duchenne muscular dystrophy (DMD). The company also has an Exosome protein-based vaccine in preclinical trial to treat SARS-CoV-2, a StealthX Exosome Platform, and an exosome platform program for vaccine and therapeutic development in preclinical trial.
In its 10-K report, Capricor Therapeutics, Inc. provided an overview of its financial condition and results of operations. As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling approximately $318.1 million. However, it reported substantial operating losses, with net losses of approximately $105.0 million and $40.5 million for the years ended December 31, 2025, and 2024, respectively. As of December 31, 2025, the company had an accumulated deficit of approximately $304.9 million. Capricor Therapeutics, Inc. indicated that it expects to incur significant expenses and operating losses for the foreseeable future as it seeks to develop and commercialize its product candidates.
The company emphasized that its ability to generate product revenue and achieve profitability will depend on the successful development, regulatory approval, and commercialization of Deramiocel and any other product candidates it may develop. Capricor Therapeutics, Inc. also highlighted its intention to finance its operations through a combination of public or private equity financings, debt financings, or other sources, including licensing agreements or strategic collaborations. It emphasized the need for additional funding to support its continuing operations, stating that it may be unable to raise additional funds or enter into such agreements or arrangements when needed on favorable terms, if at all.
In terms of its revenue, Capricor Therapeutics, Inc. reported no clinical development income for the year ended December 31, 2025, compared to approximately $22.3 million in 2024. The company attributed the decline to the full recognition of $50.0 million in development milestone payments received from Nippon Shinyaku in 2024, related to the Exclusive Commercialization and Distribution Agreement.
The 10-K report also highlighted the company's research and development expenses, which primarily consist of compensation and other related personnel costs, supplies, clinical trial costs, and patient treatment costs. Capricor Therapeutics, Inc. noted that it expects to record additional non-cash compensation expense in the future, which may be significant.
Following these announcements, the company's shares moved 1.29%, and are now trading at a price of $24.35. For the full picture, make sure to review CAPRICOR THERAPEUTICS, INC.'s 10-K report.
